Spots Global Cancer Trial Database for Liquid Biopsy for Detection of Driver Mutation in NSCLC
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Liquid Biopsy for Detection of Driver Mutation in NSCLC
Official Title: Liquid Biopsy for Detection of Driver Mutation in Diagnostic and Prognostic of NSCLC
Study ID: NCT02778854
Conditions
Interventions
Study Description
Brief Summary: The purpose of this study is to evaluate the diagnostic and prognostic efficacy of liquid biopsy in different specimens and in different methods compared with tissue detection .
Detailed Description: Collect plasma and other specimens from patients who are newly diagnosed with NSCLC or with drug-resistant and plan to receive gene detection to complete the diagnostic test for liquid biopsy .Participants who come from diagnostic test and plan to receive tyrosine kinase inhibitors (TKI) therapy will be collected plasma and other specimens every month during the regiments and monitor the changes of driver motion to predict the prognosis of targeted therapy.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
department of respiratory department ,Chinese PLA general hospital, Beijing, Beijing, China
Contact Details
Name: Liang-an Chen, MD,PHD
Affiliation: Chinese PLA General Hospital
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
